BROWSE ICAAC 2009 COVERAGE
|
ICAAC 2009 Newsroom
- ICAAC Update (January/February 2010)
Three new drugs in development, plus Isentress with Reyataz.
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- HIV Antiretrovirals in Development: An Update From ICAAC 2009 (October 22, 2009)
In The 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
- Can a Trofile Assay Be Used to Predict HIV Disease Progression? (September 20, 2009)
An interview with Matthew Goetz, M.D.
In The 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
- In the MERIT Trial, Maraviroc Decreased Levels of Immune Activation Earlier Than Efavirenz (September 14, 2009)
An interview with Nick Funderburg, M.D.
In The 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
- Raltegravir Exhibits More Lipid-Friendly Profile Than Efavirenz, STARTMRK Subanalysis Finds (September 14, 2009)
An interview with Edwin DeJesus, M.D.
In The 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
- Vicriviroc Safe and Effective in Treatment-Experienced HIV-Infected Patients at 96 Weeks (September 13, 2009)
An interview with Lisa Dunkle, M.D.
In The 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
- Virologic Suppression Is Less Likely Among Antiretroviral-Experienced Black Women. But Why? (September 13, 2009)
An interview with Kimberly Smith, M.D., M.P.H.
In The 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
- The Evolution of HIV Testing in the U.S.: Are We at the Cusp of a New Era? (September 12, 2009)
In The 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBody.com
|
Advertisement
|
Email
Glossary